Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord mesenchymal stem cells (Tianjin Weikai Bioengineering)
- Development stage
- Unknown
- Lead developer
- Tianjin Weikai Bioengineering
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord mesenchymal stem cells (UC-MSCs) developed by Tianjin Weikai Bioengineering are an allogeneic cell therapy investigated for the treatment of acute-on-chronic liver failure (ACLF). These cells are isolated from the Wharton's jelly of human umbilical cords and expanded in vitro. In patients with ACLF, UC-MSCs are typically administered via intravenous infusion as an adjunct to standard medical therapy. The therapeutic effect is primarily attributed to their potent immunomodulatory properties and the secretion of paracrine factors, such as hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF). These factors promote hepatocyte survival, reduce systemic inflammation by modulating T-cell and macrophage activity, and stimulate endogenous liver regeneration and angiogenesis, thereby addressing the severe liver injury and systemic inflammatory response characteristic of ACLF.
- Other names
- umbilical cord-derived mesenchymal stem cellshuman umbilical cord mesenchymal stem cellsmesenchymal stem cells
Beyond the preview
Go deeper on umbilical cord mesenchymal stem cells (Tianjin Weikai Bioengineering).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (Tianjin Weikai Bioengineering).